Tuesday , December 1 2020
Home / Brad Delong, Berkeley / BioNTech 90% Effective Messenger RNA COVID Vaccine?

BioNTech 90% Effective Messenger RNA COVID Vaccine?

Summary:
Https://www.icloud.com/keynote/0aP8gr2_cfSeHzTQEw9OVC6hg Little additional information seems to be available at this moment: Pfizer and BioNTech (2020-11-09): Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study https://www.businesswire.com/news/home/20201109005539/en/: ‘Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected. Submission for

Topics:
Bradford DeLong considers the following as important:

This could be interesting, too:

Bradford DeLong writes Briefly Noted for 2020-11-28

Bradford DeLong writes Briefly Noted for 2020-11-26

Bradford DeLong writes Boehlert: A Crack in the Noise Machine: How Murdoch Derailed Trump—Noted

Bradford DeLong writes Briefly Noted for 2020-11-25

https://www.icloud.com/keynote/0aP8gr2_cfSeHzTQEw9OVC6hg

Little additional information seems to be available at this moment:

Pfizer and BioNTech (2020-11-09): Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study https://www.businesswire.com/news/home/20201109005539/en/: ‘Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. Analysis evaluated 94 confirmed cases of COVID-19 in trial participants. Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected. Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November. Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints…


Bojan Pancevski & Jared S. Hopkins (2020-10-22): How Pfizer Partner BioNTech Became a Leader in Coronavirus Vaccine Race https://www.wsj.com/articles/how-pfizer-partner-biontech-became-a-leader-in-coronavirus-vaccine-race-11603359015: ‘MAINZ, Germany—On a Friday in late January, Ugur Sahin received an email with bad news: A new study of a deadly new coronavirus in China suggested it was more infectious than previously believed. The outbreak, he believed, had the potential to grow into a pandemic. The following Monday, the German scientist and chief executive of biotech firm BioNTech SE summoned his board to announce that the company, which had been developing next-generation cancer treatments, would start work on a Covid-19 vaccine. Human trials would need to start by April, he added, in case Europe and the U.S. had to go into lockdowns. Ugur Sahin, co-founder and chief executive of BioNTech, led the company to focus on coronavirus research early in the pandemic. While much of the world was still oblivious to the danger, BioNTech was scrambling, Dr. Sahin told The Wall Street Journal earlier this month…


BioNTech: '“Our vaccine consists of a short segment of… messenger RNA… provid[ing] instructions for a human cell to make a harmless version of a target protein,… which activates the body’s immune response against the SARS-CoV-2 virus. We expect that our vaccination approach will stimulate the immune system to generate protective antibodies. This means the immune systems learns how to recognize the SARS-CoV-2 virus upon exposure and prevent subsequent infection. Unlike other vaccines, mRNA vaccines do not contain the virus itself and therefore pose no risk of infection…

.#coronavirus #noted #2020-11-09
Bradford DeLong
J. Bradford DeLong is Professor of Economics at the University of California at Berkeley and a research associate at the National Bureau of Economic Research. He was Deputy Assistant US Treasury Secretary during the Clinton Administration, where he was heavily involved in budget and trade negotiations. His role in designing the bailout of Mexico during the 1994 peso crisis placed him at the forefront of Latin America’s transformation into a region of open economies, and cemented his stature as a leading voice in economic-policy debates.

Leave a Reply

Your email address will not be published. Required fields are marked *